Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Edematous Clear all
Completed Phase 2 Interventional Results available

A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

NCT01673191
View directory record Official record
Conditions
Macular Edema, Diabetes Mellitus
Interventions
Dexamethasone intravitreal implant, Steroid plus NSAID eye drop combination therapy
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 14, 2026, 9:41 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Grasshopper: a Novel Clinical Dashboard for Radiologists

NCT06785246
View directory record Official record
Conditions
Chest Infection, Pulmonary Edema - Acute
Interventions
Grasshopper dashboard
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Sep 14, 2026, 9:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate

NCT01314417
View directory record Official record
Conditions
Non-infectious Intermediate and Posterior Uveitis
Interventions
Methotrexate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 4 Interventional Results available

Lymphedema Study for Arm or Leg Lymphedema

NCT02257970
View directory record Official record
Conditions
Lymphedema
Interventions
Ketoprofen, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 14, 2026, 9:41 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Tranexamic Acid in Nasal Mohs Reconstruction

NCT06057675
View directory record Official record
Conditions
Postoperative Bleeding, Skin Cancer Face
Interventions
Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine), Control (1% lidocaine with 1:100,000 epinephrine)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 14, 2026, 9:41 AM EDT
Not yet recruiting Phase 2 Interventional

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07729137
View directory record Official record
Conditions
Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation, Corneal Endothelial Cell Loss, Corneal Endothelial Disorder, Corneal Endothelial Dystrophy 1, Endothelial Cell Loss, Corneal, Pseudophakic Bullous Keratopathy, Pseudophakic Bullous Keratopathy (PBK)
Interventions
150K cells, 500K cells, Placebo
Biological · Procedure
Lead sponsor
Emmecell
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

NCT04503551
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Not applicable Interventional Results available

Triamcinolone vs. Laser for Diabetic Macular Edema

NCT00229931
View directory record Official record
Conditions
DIABETIC MACULAR EDEMA
Interventions
Triamcinolone acetonide, laser
Drug · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Vitamin E to Treat Uveitis-Associated Macular Edema

NCT00021645
View directory record Official record
Conditions
Cystoid Macular Edema, Uveitis
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 14, 2026, 9:41 AM EDT
Completed No phase listed Observational

Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema

NCT02088229
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Sep 14, 2026, 9:41 AM EDT
Withdrawn Not applicable Interventional

Effects of Intensified Sodium Management in Hemodialysis Patients

NCT01015313
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
intensive sodium management
Other
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

NCT01471691
View directory record Official record
Conditions
Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
Interventions
ranibizumab 0.5mg, ranibizumab 1.0mg
Drug
Lead sponsor
Hanscom, Thomas, M.D.
Individual
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema

NCT00441662
View directory record Official record
Conditions
Melanoma
Interventions
Sub-Tenon triamcinolone 40mg
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

NCT03666923
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

NCT06021054
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Veligrotug, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 14, 2026, 9:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)

NCT02105298
View directory record Official record
Conditions
Respiratory Failure, Acute Respiratory Failure Requiring Reintubation, Pulmonary Edema, Pneumonia, Hypoxia, Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
104,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

NCT02363621
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3 mg, Aflibercept 2.0 mg
Drug
Lead sponsor
Arshad Khanani
Other
Eligibility
21 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 14, 2026, 9:41 AM EDT
Completed No phase listed Observational

Optical Coherence Tomography Comparative Study

NCT00069199
View directory record Official record
Conditions
Retinal Disease, Healthy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Topcon Endpoint Management

NCT01732614
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Topcon Endpoint Management laser
Procedure
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 14, 2026, 9:41 AM EDT
Terminated Phase 3 Interventional Results available

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

NCT02717442
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

OTO-104 for Meniere's Disease

NCT01084525
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104 (steroid) 3 mg, Placebo, OTO-104 (steroid) 12 mg
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

NCT07484074
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
Interventions
Faricimab, OLN324
Drug
Lead sponsor
Ollin Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
29
States / cities
Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 14, 2026, 9:41 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

NCT02559180
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
aflibercept
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 14, 2026, 9:41 AM EDT
Not listed Phase 3 Interventional

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

NCT04433949
View directory record Official record
Conditions
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Low Dose Radiation Therapy
Other · Radiation
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 14, 2026, 9:41 AM EDT